Journal of Multiple Sclerosis Research is the official open access scientific publication organ of the Multiple Sclerosis Research Association, with English as the journal’s publication language.
Journal of Multiple Sclerosis Research does not charge any fee for article submission or processing and publication. Also, manuscript writers are not paid by any means for their manuscripts.
The journal should be abbreviated as “J Mult Scler Res” when referenced.
Journal of Multiple Sclerosis Research accepts invited review articles, research articles, brief reports, case reports, letters to the editor, and images that are relevant to the scope of multiple sclerosis, neuromyelitis optica, and other related diseases of the central nervous system on the condition that they have not been previously published elsewhere. All manuscripts are subject to editorial revision to ensure they conform to the style adopted by the journal. There is a double-blind reviewing system.
The Editorial Policies and General Guidelines for manuscript preparation specified below are based on “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations)” by the International Committee of Medical Journal Editors (2013, archived at (http://www.icmje.org).
The manuscript submission and editorial review process are as follows:
After receiving each manuscript, a checklist is completed by the editorial assistant. The editorial assistant checks that each manuscript contains all required components and adheres to the author guidelines, after which time it will be forwarded to the editor in chief. Following the editor in chief’s evaluation, each manuscript is forwarded to the associate editor, who assigns reviewers. The selected reviewers (at least three) will generally review all manuscripts based on their relevant expertise. The associate editor could also be assigned as a reviewer along with the reviewers. After the reviewing process, all manuscripts are evaluated in the editorial board meeting.
The Review Process
This journal applies double-blind review, which means that the reviewers cover both the reviewer and the author identifications throughout the review process.
Each manuscript submitted to the Journal of Multiple Sclerosis Research is subject to an initial review by the editorial office to determine if it is aligned with the journal’s aims and scope and complies with essential requirements. Manuscripts (all double-blind and peer-reviewed) sent for peer review will be assigned to one of the journal’s associate editors, who is an expert on the manuscript’s content. During the review, the statistics department editor will evaluate articles that need detailed statistical evaluation. All accepted manuscripts are subject to English language editing. Once papers have been reviewed, the reviewers’ comments are sent to the editor, who will make a preliminary decision on the paper. At this stage, based on the feedback from reviewers, manuscripts can be either accepted or rejected, revisions can be recommended. Following initial peer review, articles judged worthy of further consideration often require revision. Revised manuscripts generally must be received within 3 months from the date of the initial decision and must include “point-to-point response to the comments of reviewers” and a copy of the revised text by highlighting the changes made in the revised manuscripts. Extensions must be requested from the associate editor at least 2 weeks before the 3-month revision deadline expires; Journal of Multiple Sclerosis Research will reject manuscripts received beyond the 3-month revision deadline. Manuscripts with extensive revision recommendations will be sent for further review (usually by the same reviewers) upon their re-submission. When a manuscript is finally accepted for publication, the technical editor will make a final edit, and a marked-up copy will be e-mailed to the corresponding author for review and for any final adjustments.
Preparation of Manuscript
Manuscripts should be prepared according to ICMJE guidelines (http://www.icmje.org).
Original manuscripts require a structured abstract. Each section of the structured abstract must be labelled with the appropriate subheading (Objective, Materials and Methods, Results, and Conclusion). Case reports require short unstructured abstracts, whereas letters to the editor do not require an abstract. Research or project support should be acknowledged as a footnote on the title page.
Technical and other assistance should be provided on the title page.
Preparation of research articles, systematic reviews, and meta-analyses must comply with study design guidelines:
CONSORT statement for randomized controlled trials (Moher D, Schultz KF, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991) (http://www.consort-statement.org/);
PRISMA statement of preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6(7):e1000097.) (http://www.prisma-statement.org/);
Systematic Reviews and Meta-Analyses Guidelines
STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al., for the STARD Group. Toward complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003;138:40-44.) (http://www.stard-statement.org/);
STROBE statement, a checklist of items that should be included in reports of observational studies (http://www.strobe-statement.org/);
Observational Studies Guidelines
Meta-analysis of observational Studies in Epidemiology (MOOSE) guidelines for meta-analysis and systemic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting MOOSE group. JAMA 2000;283:2008-2012).
Clinical Trial Policy
All clinical trials, which are any research projects that prospectively assign individuals or a group of people to an intervention, with or without concurrent comparison or control groups, in order to study the relationship between a health-related intervention and a health outcome, must be registered in a public trials registry acceptable to the International Committee of Medical Journals Editors (ICMJE). Authors of randomized controlled trials must adhere to the CONSORT guidelines , and provide both a CONSORT checklist (for protocols, see the SPIRIT guidance) and flow diagram. We require that you choose the MS Word template at www.consort-statement.org for the flow chart and cite/upload it in the manuscript as a figure. In addition, submitted manuscripts must include the unique registration number in the Abstract as evidence of registration. The Clinical Trial Registration Policy has been implemented in our journal as of September 2023. For more detailed instructions regarding clinical trials, please visit the guideline below:
Clinical Trials Guidelines
You can register for clinical trials by visiting the following link:
To register the relevant record in the system and learn more about the protocol to be followed, please review the link below:
The other registries are accepted by ICJME:
Manuscript Format and Style
The submission should be split into separate files in the following order:
Title: The title should provide important information regarding the manuscript’s content. The title page should include the authors’ names, degrees, and institutional/professional affiliations, a short title, abbreviations, keywords, financial disclosure statement, and conflict of interest statement. If a manuscript includes authors from more than one institution, each author’s name should be followed by a superscript number corresponding to their institution, which is listed separately. The contact information for the corresponding author should also be provided, including name, e-mail address, telephone, and fax number. The title page must contain the ORCID ID information of all authors.
Running Head: The running head should not be more than 40 characters, including spaces, and should be located at the bottom of the title.
Word Count: The word count does not include the abstract, references, or figure/table legends. The word count must be noted on the title page, along with the number of figures and tables. Original articles should be less than 3000 words and include no more than six figures, tables and 50 references.
Tables and figures: All tables and figures must be placed after the text and must be labelled.
Data Sharing Policies: Data sharing policies concern the minimal dataset that supports the central findings of a published study. Generated data should be publicly available and cited in accordance with the journal guidelines. Authors must inform the journal about the tables and figures created.
The journal expects that data supporting the results in the paper will be archived in an appropriate public repository. Authors are required to provide a data availability statement to describe the availability or the absence of shared data. When data have been shared, authors are required to include a link to the used repository in their data availability statement and to cite their shared data. Journal of Multiple Sclerosis Research requests detailed information from the authors regarding the data sharing policy.
Conflict of Interest Statement: To prevent potential conflicts of interest from being overlooked, this statement must be included in each manuscript. In case of conflicts of interest, every author should complete the ICMJE general declaration form, which can be obtained from http://www.icmje.org/coi_disclosure.pdf.
Abstract and Keywords: The second page should include an abstract not exceeding 250 words. Moreover, as various electronic databases integrate only abstracts into their index, important findings should be presented in the abstract.
The abstract should be short and factual. It should state the purpose of the research briefly and should be structured according to the following subheadings: Objective, Materials and Methods, Results, and Conclusion. Abbreviations should be avoided, and reference citations are not permitted. References should be avoided, and nonstandard or uncommon abbreviations should be avoided, but if essential, they must be defined at their first mention in the abstract itself. The clinical trial number should be provided at the end of the abstract. The abstract should be included in the main text.
Objective: The abstract should state the objective (the purpose of the study and hypothesis) and summarize the rationale for the study.
Materials and Methods: Important methods should be written, respectively.
Results: Important findings and results should be provided here.
Conclusion: The study’s new and important findings should be highlighted and interpreted.
Other types of manuscripts, such as case reports, reviews, and others, will be published according to uniform requirements.
Keywords: Provide at least three keywords below the abstract to assist indexers. Use terms from the Index Medicus Medical Subject Headings List (for randomized studies, a CONSORT abstract should be provided (http://www.consort-statement.org).
1. Original Articles: An article considered original research if;
It is the report of a study written by the researchers who actually did the study.
The researchers describe their hypothesis or research question and the purpose of the study.
The researchers detail their research methods.
The results of the research are reported.
The researchers interpret their results and discuss possible implications.
This is the most common type of journal manuscript used to publish full data reports from research. It may be called an Original Article, Research Article, Research, or just Article, depending on the journal.
Original articles should have the following sections:
Introduction: The introduction should include an overview of the relevant literature presented in summary form (one page), and whatever remains interesting, unique, problematic, relevant, or unknown about the topic must be specified. The introduction should conclude with the rationale for the study and its design and objective(s).
Materials and Methods: The selection of observational or experimental participants, such as patients, laboratory animals, and controls, must be clearly described, including inclusion and exclusion criteria and a description of the source population. Sufficiently detailed methods and procedures must be identified to allow other researchers to reproduce the results. References to established methods (including statistical methods) to brief modified methods and the rationale for using them and evaluation of their limitations must be provided. All drugs and chemicals used, including generic names, doses, and routes of administration, must be identified. The section should include only information that was available at the time the plan or protocol for the study was devised on STROBE (http://www.strobe-statement.org).
Statistics: The statistical methods used in enough detail to enable a knowledgeable reader with access to the original data to verify the reported results must be described. Statistically important data should be provided in the text, tables, and figures. Details about randomization and the number of observations must be provided as well, the treatment complications must be described, and all computer programs used must be specified.
Results: Your results should be presented in logical sequence in the text, tables, and figures. Not all the data provided in the tables and/or figures in the text must be presented; Only important findings, results, and observations should be emphasized and/or summarized. For clinical studies, the number of samples, cases, and controls included in the study should be provided. Discrepancies between the planned number and the obtained number of participants should be explained. Comparisons and statistically important values (i.e., p-value and confidence interval) should be provided.
Discussion: This section should include a discussion of the data. New and important findings/results and the conclusions they lead to should be emphasized. The conclusions should be linked with the goals of the study, but unqualified statements and conclusions not entirely supported by the data should be avoided. The detailed findings/results should not be repeated; important findings/results should be compared with those of similar studies in the literature, along with a summary. In other words, similarities or differences in the obtained findings/results with those previously reported should be discussed.
Study Limitations: Limitations of the study should be detailed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.
Conclusion: The conclusion of the study should be highlighted.
2. Case Reports: A case report is a detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. It usually describes an unusual or novel occurrence and remains one of the cornerstones of medical progress, and provides many new ideas in medicine. Case reports should be structured as follows:
Abstract: an unstructured abstract that summarizes the case
Introduction: a brief introduction (recommended length: 1-2 paragraphs)
Case Presentation: describes the case in detail, including the initial diagnosis and outcome
Discussion: should include a brief review of the relevant literature and how the presented case furthers our understanding of the disease process.
3. Review Articles: Review articles provide a comprehensive summary of research on a certain topic and a perspective on the state of the field and where it is heading. They are often written by leaders in a particular discipline after an invitation from the editors of a journal.
Review articles should include a conclusion in which a new hypothesis or study about the subject may be posited. Methods for literature search or level of evidence should not be published. Authors who will prepare review articles should already have published research articles on the relevant subject. There should be a maximum of two authors for review articles.
4. Images: Authors can submit for consideration an illustration and photos that are interesting, instructive, and visually attractive, along with a few lines of explanatory text and references. No abstract, discussion, or conclusion is required, but a brief title should be included.
5. Letters to the Editor: A letter to the editor (sometimes abbreviated LTTE or LTE) is a letter sent to a publication about issues of concern from its readers. In academic publishing, letters to the editor of an academic journal are usually open post-publication reviews of a paper, often critical of some aspects of the original paper. For letters to the editor, no abstract is required, but a brief title should be included.
6. Invited Review Article: Invited review articles are comprehensive analyses of specific topics in medicine, which are written upon invitation due to extensive experience and publications of authors on their view of the subjects. All invited review articles will also undergo peer review prior to acceptance.
7. Editorial Comment: Editorial comments are a brief remark on an article published in the journal by the viewer of their article or by a relevant authority. Most comments are invited by the editor in chief, but spontaneous comments are welcome. An abstract is not required with this type of manuscript.
References: References should be cited in the text, tables, and figures with numbers in parentheses. References should be numbered consecutively according to the order in which they first appear in the text. All authors should be in the references. Journal of Multiple Sclerosis Research research adheres to the NLM style.
Examples of References
1. List All Authors
Bonanni E, Tognoni G, Maestri M, Salvati N, Fabbrini M, Borghetti D, DiCoscio E, Choub A, Sposito R, Pagni C, Iudice A, Murri L. Sleep disturbancesin elderly subjects: an epidemiological survey in an Italian district. ActaNeurol Scand 2010;122:389-397.
2. Organization as Author
American Geriatrics Society 2015 Updated Beers Criteria Expert panel. American geriatrics society 2015 updated Beer criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227-2246.
3. Complete Book
Ham RJ, Sloane PD, Warshaw GA, Potter JF, Flaherty E. Ham’s primary care geriatrics : a case-based approach, 6th ed. Philadelphia, Elsevier/Saunders, 2014.
4. Chapter in Book
BG Katzung. Special Aspects of Geriatric Pharmacology, In:Bertram G. Katzung,Susan B. Masters, Anthony J. Trevor (Eds). Basic and Clinical Pharmacology. 10th edition, Lange, Mc Graw Hill, USA 2007, pp 983-990.
Reichenbach S, Dieppe P, Nuesch E, Williams S, Villiger PM, Juni P. Association of bone attrition with knee pain, stiffness and disability; a cross sectional study. Ann Rheum Dis 2011;70:293-298. (abstract).
6. Letter to the Editor
Rovner B. The Role of the Annals of Geriatric Medicine and Research as a Platform for Validating Smart Healthcare Devices for Older Adults. Ann Geriatr 2017;21:215-216.
Garfinkel D. The tsunami in 21st century healthcare: The age-related vicious circle of co-morbidity - multiple symptoms - over-diagnosis - over treatment - polypharmacy [abstract]. J Nutr Health Aging 2013;17(Suppl 1):224-227.
Tables, Graphics, Figures, and Images
Tables: Each table should be supplied on a separate file. Tables should be numbered according to the order in which they appear in the text, and a brief caption for each should be supplied. Each column must have a short or abbreviated heading. Explanatory statistical measures of variation, such as standard deviation or standard error of the mean, must be written. Each table must be cited in the text.
Figures: Figures should be professionally drawn and/or photographed. Figures should be numbered according to the order in which they appear in the text. Figures include graphs, charts, photographs, and illustrations. Each figure should be accompanied by a legend that does not exceed 50 words. Abbreviations must be used only if they have been introduced in the text. Authors are also required to provide the level of magnification for histological slides. The internal scale must be explained, and the staining method used must be identified. Figures should be submitted as separate files, not in the text file. High-resolution image files are not preferred for initial submission as the file sizes may be too large. The total file size of the PDF for peer review should not exceed 5 MB.
|Type of Article
|Number of References
|Invited Review Article
|Letters to the Editor
|*Excludes abstract, acknowledgements, conflict of interest statement, references and tables; maximum word counts.
Each author should have participated sufficiently in work to assume public responsibility for the content. Any portion of a manuscript that is critical to its main conclusions must be the responsibility of at least one author. Please check the definition of the role of authors and contributors in the following link:
All submissions should contain a contributor’s statement page. Each manuscript should contain substantial contributions to idea and design, acquisition of data, or analysis and interpretation of findings. All persons designated as an author should qualify for authorship, and all those that qualify should be listed. Each author should have participated sufficiently in the work to take responsibility for appropriate portions of the text.
The support received from individuals, organizations, grants, corporations, and any other source should be acknowledged. For work involving a biomedical product or potential product partially or wholly supported by corporate funding, a note stating “This study was financially supported (in part) with funds provided by (company name) to (authors’ initials)” must be included. Grant support, if received, needs to be stated, and the specific granting institutions’ names and grant numbers provided when applicable.
Authors are expected to disclose on the title page any commercial or other associations that might pose a conflict of interest in connection with the submitted manuscript. All funding sources that supported the work and the institutional and/or corporate affiliations of the authors should be acknowledged on the title page.
When reporting experiments conducted with humans, it must be indicated that the procedures were in accordance with ethical standards set forth by the committee that oversees human experimentation. Approval of research protocols by the relevant ethics committee, in accordance with international agreements (“Helsinki Declaration of 1975, revised 2013” and “Guide for the Care and Use of Laboratory Animals”) is required for all experimental, clinical, and drug studies. Studies performed on humans require an ethics committee certificate, including an approval number. It also should be indicated in the “Materials and Methods” section. Patient names, initials, and hospital identification numbers should not be used. Manuscripts reporting the results of experimental investigations conducted with humans must state that the study protocol received institutional review board approval and that the participants provided informed consent.
Noncompliance with scientific accuracy is not in accord with scientific ethics.
Plagiarism is a serious problem and the most common ethical issue afflicting medical writing.
Journal of Multiple Sclerosis Research does not allow any form of plagiarism. In accordance with our journal policy, submitted manuscripts are screened with plagiarism software to detect instances of overlapping and similar text (iThenticate) at least two times (during the evaluation process and after acceptance).
Conditions of Publication
All authors are required to affirm the following statements before their manuscript is considered:
Submission is considered on the condition that papers are previously unpublished and are not offered simultaneously elsewhere, that all authors have read and approved the content, that authors have declared all competing interests, and that the work has been conducted under internationally accepted ethical standards after relevant ethical review.
All authors are responsible for the manuscript’s content.
All authors participated in the study concept and design, analysis and interpretation of the data, and drafting or revising of the manuscript and have approved the manuscript as submitted. In addition, all authors are required to disclose any professional affiliation, financial agreement, or other involvement with any company whose product figures are prominent in the submitted manuscript.
Authors of accepted manuscripts will receive electronic page proofs and are responsible for proofreading and checking the entire article within 2 days. Failure to return the proof in 2 days will delay publication. If the authors cannot be reached by e-mail or telephone within 2 weeks, the manuscript will be rejected and will not be published in the journal.
Abbreviations and Symbols
Use only standard abbreviations. Avoid abbreviations in the title and abstract. The full term for an abbreviation should precede its first use in the text unless it is a standard abbreviation. All acronyms used in the text should be expanded at first mention, followed by the abbreviation in parentheses; thereafter, the acronym only should appear in the text. Acronyms may be used in the abstract if they occur three or more times therein but must be reintroduced in the body of the text. Generally, abbreviations should be limited to those defined in the AMA Manual of Style, current edition. A list of each abbreviation (and the corresponding full-term) used in the manuscript must be provided on the title page.
The ORCID (Open Researcher and Contributor ID) number of the corresponding author should be provided while sending the manuscript. A free registration can be created at http://orcid.org.
Multiple Sclerosis Research Association
Address: Korutürk Mah. V. Hüseyin Öğütçen Cad. No: 45/B D: 8 Balçova,İzmir/Turkey
Phone: +90 (232) 484 74 80
E-mail: [email protected]
Galenos Publishing House
Address: Molla Gürani Mah. Kaçamak Sok. 21/1 Fındıkzade, Fatih, Istanbul/Turkey
Phone: +90 212 621 99 25
Fax: +90 212 621 99 27
Web page: http://www.galenos.com.tr
E-mail: [email protected]